Left Ventricular Outflow Tract Obstruction (LVOTO)
Definition
Dynamic obstruction to left ventricular systolic outflow, caused in hypertrophic cardiomyopathy (HCM) by systolic anterior motion (SAM) of the mitral valve leaflet contacting the interventricular septum. By convention a peak instantaneous Doppler gradient of ≥30 mmHg defines obstruction; ≥50 mmHg is the point at which the gradient becomes haemodynamically significant and is the usual threshold for septal reduction. (sources/esc-cmp-2023, rating: very high)
The 30–50 mmHg range is not a treatment threshold. Most patients with a maximum resting or provoked gradient below 50 mmHg are managed as non-obstructive disease, but the ESC guideline permits invasive gradient reduction in a small, selected group with gradients of 30–50 mmHg and no other obvious cause of symptoms — while conceding that data for that group are lacking. (sources/esc-cmp-2023)
Key Concepts
- It is the common phenotype, not the exception. Approximately 70% of patients with HCM have subaortic muscular obstruction that can be provoked or exacerbated by exercise or any other stimulus to contractility. (sources/HCM-NEJM-2025, rating: very high)
- The mechanism is mechanical but the driver is sarcomeric. SAM produces the obstruction; excess actin–myosin cross-bridge cycling produces the hyperdynamic ventricle that permits SAM, which is why cardiac myosin inhibitors work and why they fail when there is no obstruction to relieve.
- The gradient is not a fixed number. Heart rate, preload, afterload, contractility, activity, food and alcohol all move it, so a single resting value can badly misrepresent the patient.
- Diagnosis is Doppler-based and sequential: rest, Valsalva, standing, then exercise echocardiography if still unexplained; catheterisation for uncertain severity, before septal reduction, or to distinguish fixed from dynamic obstruction.
- The two guidelines diverge at step 3, not at step 1: both start with beta-blockers and both reach septal reduction, but ESC 2023 places disopyramide above mavacamten, while AHA 2024 makes mavacamten, disopyramide and septal reduction equivalent Class 1 options.
Epidemiology
- Approximately 70% of HCM patients have resting or provocable subaortic obstruction; the remainder have non-obstructive HCM — put at 30–50% of the population in some estimates — for which no pharmacotherapy is approved. (sources/HCM-NEJM-2025, rating: very high; sources/mavacamten-odysseyhcm-nejm-2025, rating: very high)
- Obstruction is the major cause of exertional symptoms and contributes to sudden cardiac death risk assessment. (sources/esc-cmp-2023, rating: very high)
- The gradient is one of the variables in the HCM Risk-SCD model, alongside age, unexplained syncope, maximum wall thickness, left atrial diameter, non-sustained VT, family history and LV systolic function. (sources/esc-cmp-2023)
Pathophysiology and Provocation
- SAM mechanism. The mitral leaflet is drawn anteriorly during systole, contacts the hypertrophied septum, and creates an obstruction that worsens as systole progresses — hence the late-peaking gradient. (sources/esc-cmp-2023, rating: very high)
- Sarcomere hypercontractility is the driver. Excess cross-bridge cycling generates the hyperdynamic, hypercontractile state that promotes SAM, and is the pharmacological target of cardiac myosin inhibitors. (sources/aficamten-maplehcm-nejm-2025, rating: very high)
- Aggravating factors — tachycardia, reduced preload (dehydration, diuretics, vasodilators), reduced afterload, and positive inotropes all worsen the gradient. (sources/HCM-AHA-2024, rating: very high)
- The gradient moves through the day, varying with heart rate, blood pressure, volume status, activity, medications, food and alcohol intake — which is why symptom response, not the measured number, guides drug titration. (sources/HCM-AHA-2024)
- Pressure contour. Dynamic obstruction produces a spike-and-dome aortic trace — a rapid initial upstroke at valve opening followed by a late systolic pressure fall as obstruction develops — with late-peaking LV pressure. Fixed valvular obstruction instead gives a parvus et tardus upstroke. (sources/hemodynamics-circ-2012, rating: high)
Echocardiographic Diagnosis
- Protocol (Class I, Level B). Two-dimensional Doppler echocardiography at rest and during Valsalva in the sitting and semi-supine positions, then standing if no gradient is provoked. If the patient is symptomatic and the resting or Valsalva gradient is <50 mmHg, add exercise stress echocardiography. (sources/esc-cmp-2023, rating: very high)
- Gradient thresholds. ≥30 mmHg = obstruction present; ≥50 mmHg = haemodynamically significant and the usual treatment threshold. (sources/esc-cmp-2023)
- Transoesophageal echocardiography clarifies mechanism before an invasive procedure. (sources/esc-cmp-2023)
- Dobutamine provocation is not advised — it is not physiological and is poorly tolerated. (sources/esc-cmp-2023)
Invasive Haemodynamic Assessment
- Spike-and-dome aortic contour distinguishes dynamic from fixed obstruction at the time of catheterisation. (sources/hemodynamics-circ-2012, rating: high)
- Braunwald–Brockenborough sign. On the post-premature-ventricular-contraction beat, dynamic LVOTO shows a decrease in aortic pulse pressure (post-extrasystolic potentiation worsens obstruction), whereas fixed valvular stenosis shows an increase. (sources/hemodynamics-circ-2012)
- Isoproterenol provocation. Where Valsalva and PVC induction fail to produce a gradient ≥50 mmHg, isoproterenol simulates exercise and can unmask labile obstruction before septal ablation; it is also used after the procedure to confirm adequate gradient reduction. (sources/hemodynamics-circ-2012)
- Technical caution. Catheters readily entrap in the hypertrophied hyperdynamic ventricle and give erroneous pressures; a transseptal approach is preferred, and if retrograde access is used, a multipurpose or Rodriguez catheter with distal side holes is preferred over a long-sidehole pigtail. (sources/hemodynamics-circ-2012)
Pharmacological Management
| Step | ESC 2023 | AHA 2024 |
|---|---|---|
| 1 | Non-vasodilating beta-blocker titrated to maximum tolerated dose — I B | Beta-blocker — 1 |
| 2 | Verapamil or diltiazem if beta-blocker is contraindicated or ineffective — I | Non-dihydropyridine calcium-channel blocker substitution — 1 B-NR |
| 3 | Disopyramide added to beta-blocker — I, with QTc monitoring and dose reduction above 500 ms | Myosin inhibitor (adults), or disopyramide with an AV nodal blocker, or septal reduction — 1 B-R |
| 4 | Mavacamten — IIa A | — (elevated to step 3) |
| Asymptomatic, gradient ≥50 mmHg | Beta-blocker or verapamil may be considered — IIb | — |
| Verapamil cautions | Second-line for obstruction — I | Class 3: Harm with severe dyspnoea at rest, hypotension, resting gradient >100 mmHg, or age <6 weeks |
(Sources: sources/esc-cmp-2023, rating: very high; sources/HCM-AHA-2024, rating: very high)
- Myosin inhibitors must not be combined with disopyramide, though they may be given with a beta-blocker or calcium-channel blocker. In patients with true contraindications to all three conventional agents they may be used as monotherapy. (sources/esc-cmp-2023, rating: very high)
- Vasodilators and digoxin. Discontinuation of ACE inhibitors, ARBs, dihydropyridine calcium-channel blockers or digoxin may be reasonable, because each can worsen dynamic obstruction (AHA 2b C-EO); digoxin, nitrates and phosphodiesterase inhibitors are the agents to avoid. (sources/HCM-AHA-2024, rating: very high)
- Low-dose diuretics may be considered for persistent dyspnoea with volume overload and high filling pressures, with hypovolaemia avoided — 2b C-EO (AHA), IIb C (ESC). (sources/HCM-AHA-2024)
- Acute hypotension that does not respond to fluids is treated with intravenous phenylephrine or another pure vasoconstrictor, alone or with a beta-blocker — 1 C-LD. (sources/HCM-AHA-2024)
Invasive Management
- ESC indication: gradient ≥50 mmHg with NYHA III–IV symptoms refractory to maximal drug therapy. (sources/esc-cmp-2023, rating: very high)
- AHA indication: severe dyspnoea or chest pain, usually NYHA III–IV, with a peak gradient ≥50 mmHg at rest or on physiological provocation, systolic anterior motion, and sufficient anterior septal thickness for the procedure. (sources/HCM-AHA-2024, rating: very high)
- Options are surgical myectomy and alcohol septal ablation; the choice, outcomes and complication rates are covered in concepts/Septal-Reduction-Therapy.
- Asymptomatic obstruction is not an indication for an invasive procedure; pharmacological treatment may be considered in selected cases (Class IIb). (sources/esc-cmp-2023)
Cardiac Myosin Inhibitors
| Trial | Population and design | Primary endpoint | Gradient effect | LVEF <50% |
|---|---|---|---|---|
| EXPLORER-HCM (Lancet 2020) | N=251; symptomatic obstructive HCM; 30 weeks; mavacamten vs placebo on background therapy | pVO2 + NYHA composite 37% vs 17% (P=0.0005) | Post-exercise −35.6 mmHg; 74% vs 21% below 50 mmHg | 5.7% |
| SEQUOIA-HCM (NEJM 2024) | N=282; 24 weeks; aficamten vs placebo on background therapy | Peak VO2 +1.7 ml/kg/min (P<0.001) | Valsalva −50 mmHg; 49.3% vs 3.6% below 30 mmHg | 3.5% |
| MAPLE-HCM (NEJM 2025) | N=175; 24 weeks; aficamten vs metoprolol, double-dummy, monotherapy | Peak VO2 +2.3 ml/kg/min favouring aficamten (P<0.001) | Valsalva −40.7 vs −3.8 mmHg | 1% vs 0% |
(Sources: sources/mavacamten-explorer-hcm-lancet-2020, rating: very high; sources/aficamten-sequoiahcm-nejm-2024, rating: very high; sources/aficamten-maplehcm-nejm-2025, rating: very high)
- Metoprolol lowered heart rate by 23.4 bpm without moving the gradient — a −3.8 mmHg change — and NT-proBNP and LAVi rose while peak VO2 fell. The beta-blocker effect appears to be largely chronotropic rather than haemodynamic. (sources/aficamten-maplehcm-nejm-2025, rating: very high)
- The benefit reverses on withdrawal. SEQUOIA-HCM showed gradients, KCCQ-CSS and LVEF returning toward baseline after a 4-week washout, so these agents act on physiology rather than on remodelling. (sources/aficamten-sequoiahcm-nejm-2024, rating: very high)
- Efficacy depends on there being obstruction to relieve. In non-obstructive HCM, ODYSSEY-HCM missed both co-primary endpoints (peak VO2 +0.47 ml/kg/min, P=0.07; KCCQ-CSS +2.7 points, P=0.06) while still cutting NT-proBNP by 59%, and produced LVEF <50% in 21.5% versus 1.7% of placebo patients with more serious heart-failure events. (sources/mavacamten-odysseyhcm-nejm-2025, rating: very high)
- LVEF surveillance is mandatory. A fall below 50% requires interruption and dose reduction, with restart only if LVEF recovers. (sources/HCM-AHA-2024, rating: very high)
- Trial-level comparisons belong with the drugs: see entities/Mavacamten and entities/Aficamten.
Contradictions / Open Questions
- Mavacamten sits at Class I in the United States and Class IIa in Europe. AHA 2024 makes it a step-3 option equivalent to disopyramide or septal reduction; ESC 2023 places it below disopyramide, and only after that agent has failed or is not tolerated. No head-to-head trial against disopyramide or septal reduction exists, so the two tiers are committee interpretations of the same EXPLORER and VALOR data. (sources/HCM-AHA-2024, rating: very high; sources/esc-cmp-2023, rating: very high)
- Verapamil is simultaneously a second-line therapy and a harmful drug. ESC 2023 lists verapamil or diltiazem as Class I when beta-blockers fail; AHA 2024 designates verapamil Class 3: Harm in severe resting dyspnoea, hypotension, resting gradients above 100 mmHg, and infants under 6 weeks. Both are defensible — the harm is phenotype-specific — but a reader looking for one answer will not find it. (sources/HCM-AHA-2024; sources/esc-cmp-2023)
- First-line beta-blockade is now evidence-challenged. Both guidelines make beta-blockers step 1, yet MAPLE-HCM showed aficamten monotherapy superior on every objective endpoint including peak VO2, and metoprolol failed to reduce the gradient at all. The counter-argument is that MAPLE-HCM did not test the guideline sequence — beta-blocker first with a myosin inhibitor added — which remains untested and may be better than either drug alone. (sources/aficamten-maplehcm-nejm-2025, rating: very high; sources/HCM-AHA-2024; sources/esc-cmp-2023)
- The gradient explains symptoms poorly, and the 30–50 mmHg range is evidence-free. Many patients with severe obstruction are asymptomatic — most asymptomatic LVOTO needs no treatment — while symptomatic patients frequently have no provocable gradient. The guideline's permission for invasive reduction at 30–50 mmHg in selected cases rests on no comparative data, and the boundary between "obstructive" and "non-obstructive" is a threshold of convention rather than of mechanism. (sources/esc-cmp-2023, rating: very high)
- Pharmacological provocation is discouraged in one setting and used in another. ESC advises against dobutamine because it is non-physiological and poorly tolerated, yet the cath lab relies on isoproterenol — a direct beta agonist with the same conceptual objection — to unmask labile obstruction before septal ablation. The difference is setting and supervision rather than physiology, and no study compares the two strategies' predictive value. (sources/esc-cmp-2023; sources/hemodynamics-circ-2012, rating: high)
Connections
- The disease it defines: entities/HCM — obstruction is the defining phenotype in roughly 70% and the target of every therapy on this page
- The fixed-obstruction differential: concepts/Aortic-Stenosis — parvus et tardus and a post-PVC increase in pulse pressure, against the spike-and-dome and post-PVC decrease of dynamic obstruction
- The procedural alternative: concepts/Septal-Reduction-Therapy — myectomy and alcohol ablation, their indications and outcomes
- Drugs that act on it, or against it: entities/Mavacamten · entities/Aficamten · entities/Cardiac-Glycosides — digoxin worsens dynamic obstruction
- Provocation and exertion: concepts/HCM-Exercise · concepts/Pharmacological-Provocation-Testing — exercise unmasks what rest does not
- Prognosis: concepts/HCM-Risk-SCD — the gradient is one variable in the risk model, not a stand-alone indication for an ICD
Sources
Guidelines
Reviews and haemodynamics
Trials